ArticleJournal of inorganic biochemistry2011
Preparation, characterization and in vivo assessment of Gd-albumin and Gd-dendrimer conjugates as intravascular contrast-enhancing agents for MRI.
Article in Journal of inorganic biochemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- A Manganese Porphyrin Platform for the Design and Synthesis of Molecular and Targeted MRI Contrast Agents.International journal of molecular sciences · 2023Article
- Safety Challenges and Application Strategies for the Use of Dendrimers in Medicine.Pharmaceutics · 2022Review
- Recent Advances in Gadolinium Based Contrast Agents for Bioimaging Applications.Nanomaterials (Basel, Switzerland) · 2021Review
- Functionalized nanoparticles with targeted antibody to enhance imaging of breast cancer in vivo.Journal of nanobiotechnology · 2020Article
- Click Chemistry in the Development of Contrast Agents for Magnetic Resonance Imaging.Topics in magnetic resonance imaging : TMRI · 2016Review
- Dendrimer antibody conjugate to target and image HER-2 overexpressing cancer cells.Oncotarget · 2016Article
- Gadolinium(III) Complexes with N-Alkyl-N-methylglucamine Surfactants Incorporated into Liposomes as Potential MRI Contrast Agents.Bioinorganic chemistry and applications · 2015Article
- A self-internalizing mitochondrial TSPO targeting imaging probe for fluorescence, MRI and EM.RSC advances · 2014Article
- Analysis of Lanthanide Complex Dendrimer Conjugates for Bimodal NIR and MRI Imaging.Macromolecules · 2012Article
- Silica microparticles as a solid support for gadolinium phosphonate magnetic resonance imaging contrast agents.Journal of the American Chemical Society · 2012Article
- Preparation of cystamine core dendrimer and antibody-dendrimer conjugates for MRI angiography.Molecular pharmaceutics · 2012Article
- Design of nanovectors for therapy and imaging of cardiovascular diseases.Methodist DeBakey cardiovascular journal · 2012Article
- Nanoformulations for molecular MRI.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
We report in vivo and in vitro MRI properties of six gadolinium-dendrimer and gadolinium-albumin conjugates of derivatized acyclic diethylenetriamine-N,N',N',N″, N″-pentaacetic acid (1B4M) and macrocyclic 1,4,7,10-tetraazacyclododecane-N,N',N″,N‴-tetraacetic acid (C-DOTA). The three albumin-based agents have comparable protein to chelate ratios (1:16-18) as well as molar relaxivity (8.8-10.4 mM(-1) s(-1)). The three dendrimer based agents have blood clearance half-lives ranging from 17 to 66 min while that of the three albumin-based agents are comparable to one another (40-47 min). The dynamic image obtained from use of the albumin conjugate based on the macrocycle (C-DOTA) showed a higher contrast compared to the remaining two albumin based agents. Our conclusion from all of the results is that the macrocyclic-based (DOTA) agents are more suitable than the acyclic-based (1B4M) agent for in vivo use based on their MRI properties combined with the kinetic inertness property associated with the more stable Gd(III) DOTA complex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.